Antibiotics and Antimycotics Market is expected to reach US$ 91,546.07 Million by 2031

Penicillins to Lead Antibiotics and Antimycotics Market Based on Drug Class During 2023–2031

According to our new research study on "Antibiotics and Antimycotics Market Forecast to 2031 – Global Analysis – by Drug Class, Indication, Route of Administration, and Distribution Channel," the market was valued at US$ 61,207.98 million in 2023 and is projected to reach US$ 91,546.07 million by 2031; it is expected to register a CAGR of 5.2% from 2023 to 2031. Major factors driving the market growth include the increasing prevalence of infectious diseases and growing awareness about fungal infections.

Antibiotics and antimycotics are antimicrobial agents targeting different types of bacteria and fungi, respectively. Antibiotics are further classified into bactericidal antibiotics such as penicillins and cephalosporins (which kill bacteria) and bacteriostatic antibiotics such as tetracyclines and macrolides (which inhibit bacterial growth). The effectiveness of antibiotics is challenged by the rise of antibiotic-resistant strains. Antimycotics are essential in treating conditions such as candidiasis and aspergillosis. They work by targeting various aspects of fungal cell structures or metabolism. Common classes of antimycotics include azoles (fluconazole), polyenes (amphotericin B), and echinocandins (caspofungin).

Antibiotics and Antimycotics Market, by Region, 2023 (%)

Source: The Insight Partners Analysis

Antibiotics and Antimycotics Market Analysis Based on Segmental Evaluation:

Based on drug class, the antibiotics and antimycotics market is categorized into penicillins, cephalosporins, carbapenems, macrolides, aminoglycosides, quinolones, sulfonamides, tetracyclines, azoles, and others. In 2023, the penicillins segment held a significant antibiotics and antimycotics market share. Penicillins, the most common group of broad-spectrum antibiotics, are used for the treatment of various bacterial infections caused to the ear, urinary tract, throat, teeth, and other body parts. Different types of penicillins available in the market include penicillin V, amoxicillin, penicillin G, and ampicillin. In May 2022, Phathom Pharmaceuticals, Inc. received US Food and Drug Administration (FDA) approval for VOQUEZNA DUAL PAK (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) used for the treatment of Helicobacter pylori (H. pylori) infections in adults. Amoxicillin and ampicillin are the most commonly used antibiotics for the treatment and management of Gram-positive bacterial infections. As per the Advances in Botanical Research article published by Elsevier B.V., the Gram-positive bacterial species are responsible for 65.5% of bacterial infections, and 69% of these are hospital-associated infections, while 31% are community-associated cases. The increasing prevalence of infections caused by Gram-positive bacteria is expected to contribute to the antibiotics and antimycotics market growth in the coming years.

The scope of the antibiotics and antimycotics market report includes the assessment of the market performance in North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In terms of revenue, North America dominated the antibiotics and antimycotics market share in 2023. The rising prevalence of bacterial and fungal infections, and the availability of developed healthcare infrastructure and a wide range of antibiotics and antimycotics for treatments are the factors fueling the market in this region. Additionally, an upsurge in product launches and approvals, and other strategic initiatives by prominent players are expected to create opportunities for the market growth during the forecast period.

The US antibiotics and antimycotics market growth is driven by the increasing prevalence of fungal and bacterial infections, coupled with the growing need for effective treatment options. Pneumonia is the most common respiratory infection in the US. According to Verywell Health Journal 2024 report, every year, ~1.5 million adults in the US are diagnosed with pneumonia, and ~1 million out of these are admitted to hospitals while 50,000 people die due to pneumonia or related complications. Amoxicillin and azithromycin are the most commonly used antibiotics prescribed in the US in outpatient settings for the treatment of bacterial infections. In addition, with ongoing advancements in pharmaceutical research and technology, the development of new antibiotics and antifungal agents has gained momentum, responding to the growing concerns about antibiotic resistance and the need for innovative therapies. Moreover, the growing awareness about the importance of antimicrobial stewardship programs has led to a more cautious approach to antibiotic prescription, prompting a shift toward targeted therapies and combination treatments. This is particularly evident in hospital settings, where the growing incidence of hospital-acquired infections necessitates the use of potent antimicrobials.

Key players in the antibiotics and antimycotics market are taking strategic initiatives such as product launches, product approvals, and collaborations, which are expected to support the market growth during the forecast period. For instance, in April 2024, the US Food and Drug Administration (FDA) approved Zevtera (ceftobiprole medocaril sodium for injection) for the treatment of adults suffering from Staphylococcus aureus bloodstream (SAB) infections, including those with right-sided infective endocarditis and adults suffering from acute bacterial skin and skin structure infections (ABSSSI). Additionally, in March 2023, the US FDA approved REZZAYO (rezafungin for injection) for the treatment of candidemia and invasive candidiasis.

Pfizer Inc, Novartis AG, Sanofi SA, F. Hoffmann-La Roche Ltd, Merck & Co Inc, GSK Plc, Johnson & Johnson, Cipla Ltd, Bayer AG, AbbVie Inc, and Astellas Pharma Inc. are among the leading companies profiled in the antibiotics and antimycotics market report.

Based on drug class, the antibiotics and antimycotics market is categorized into penicillins, cephalosporins, carbapenems, macrolides, aminoglycosides, quinolones, sulfonamides, tetracyclines, azoles, and others. By indication, the market is segmented into skin infections, respiratory infections, urinary tract infections, septicemia, ear infections, gastrointestinal infections, and others. In terms of route of administration, the market is segmented into oral, topical, and others. In terms of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and drug stores, and online pharmacies. Geographically, the market is categorized into North America (US, Canada and Mexico), Europe (France, Germany, UK, Spain, Italy, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, South Africa, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com